Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial
Launched by DUKE UNIVERSITY · Sep 13, 2017
Trial Information
Current as of May 16, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty" is studying how different methods of giving antibiotics before and after knee surgery might affect the risk of infections. Specifically, the researchers want to find out if giving a single dose of antibiotics right before the surgery is enough to prevent infections, or if giving antibiotics for a longer time after the surgery helps even more. The hope is to determine the best way to keep patients safe from infections during their recovery.
To participate in this trial, you need to be at least 18 years old and scheduled for a planned knee surgery due to conditions like arthritis. You should not have any open wounds or active infections in the leg that will be operated on. Participants can expect to follow a specific plan and attend scheduled visits to help the researchers gather important information. It's worth noting that Duke University is currently the only site for this study, so if you're interested, you might want to inquire there for more details.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is ≥ 18 years of age
- • Patient has no open wounds on operative leg
- • Patient is scheduled to undergo elective total knee arthroplasty for posttraumatic, osteoarthritis, avascular necrosis, and/or inflammatory arthritis
- • Patient does not have active infection on the operative leg, the operative joint
- • Patient is willing to cooperate and follow study protocol and visit schedule
- Exclusion Criteria:
- • Patient is ≤ 18 years of age
- • Patient is pregnant
- • Patient is unable to provide written consent
- • Patient has psychiatric disorder that precludes safe study participation or that necessitates confinement in a custodial environment at home or in a chronic care facility
- • Patient has traumatic injury that requires emergent or urgent total knee arthroplasty (e.g. fracture)
- • Patient has active infections in the operative leg/joint
- • Patient has severe dementia
- • Suspicion of illicit drug abuse by patient. Patients who use prescription cannabinoids are not excluded from enrollment.
- • ASA score of 5 \& 6
- • No application of topical antibiotic powder such as vancomycin or antibiotic beads in surgical wound
- • Intra-operative re-dosing other than specified re-dosing intervals or without excessive blood loss (\<1500mL)
- • History of prior native septic knee arthritis
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Durham, North Carolina, United States
San Francisco, California, United States
Baltimore, Maryland, United States
Jackson, Mississippi, United States
Atlanta, Georgia, United States
Cleveland, Ohio, United States
Columbia, South Carolina, United States
Philadelphia, Pennsylvania, United States
Charlottesville, Virginia, United States
Morton Grove, Illinois, United States
New York, New York, United States
Temple, Texas, United States
Fishersville, Virginia, United States
Irvine, California, United States
Temple Terrace, Florida, United States
Towson, Maryland, United States
Starkville, Mississippi, United States
Somerset, New Jersey, United States
Patients applied
Trial Officials
Thorsten Seyler, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials